Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 143

1.

Vimentin and laminin expression is associated with basal-like phenotype in both sporadic and BRCA1-associated breast carcinomas.

Rodríguez-Pinilla SM, Sarrió D, Honrado E, Moreno-Bueno G, Hardisson D, Calero F, Benítez J, Palacios J.

J Clin Pathol. 2007 Sep;60(9):1006-12. Epub 2006 Nov 14.

2.

Prognostic significance of basal-like phenotype and fascin expression in node-negative invasive breast carcinomas.

Rodríguez-Pinilla SM, Sarrió D, Honrado E, Hardisson D, Calero F, Benitez J, Palacios J.

Clin Cancer Res. 2006 Mar 1;12(5):1533-9.

3.

Sox2: a possible driver of the basal-like phenotype in sporadic breast cancer.

Rodriguez-Pinilla SM, Sarrio D, Moreno-Bueno G, Rodriguez-Gil Y, Martinez MA, Hernandez L, Hardisson D, Reis-Filho JS, Palacios J.

Mod Pathol. 2007 Apr;20(4):474-81. Epub 2007 Mar 2.

4.

Expression of epidermal growth factor receptor in relation to BRCA1 status, basal-like markers and prognosis in breast cancer.

Arnes JB, Bégin LR, Stefansson I, Brunet JS, Nielsen TO, Foulkes WD, Akslen LA.

J Clin Pathol. 2009 Feb;62(2):139-46. doi: 10.1136/jcp.2008.056291. Epub 2008 Aug 4.

PMID:
18682421
5.

Basal cytokeratin and epidermal growth factor receptor expression are not predictive of BRCA1 mutation status in women with triple-negative breast cancers.

Collins LC, Martyniak A, Kandel MJ, Stadler ZK, Masciari S, Miron A, Richardson AL, Schnitt SJ, Garber JE.

Am J Surg Pathol. 2009 Jul;33(7):1093-7. doi: 10.1097/PAS.0b013e31819c1c93.

PMID:
19390427
6.

Molecular profile of ductal carcinoma in situ of the breast in BRCA1 and BRCA2 germline mutation carriers.

van der Groep P, van Diest PJ, Menko FH, Bart J, de Vries EG, van der Wall E.

J Clin Pathol. 2009 Oct;62(10):926-30. doi: 10.1136/jcp.2009.065524. Epub 2009 Jun 18.

PMID:
19541683
7.

Caveolin-1 expression is associated with a basal-like phenotype in sporadic and hereditary breast cancer.

Pinilla SM, Honrado E, Hardisson D, Benítez J, Palacios J.

Breast Cancer Res Treat. 2006 Sep;99(1):85-90. Epub 2006 Mar 16.

PMID:
16541313
8.

Expression of the forkhead box transcription factor FOXP1 is associated with oestrogen receptor alpha, oestrogen receptor beta and improved survival in familial breast cancers.

Rayoo M, Yan M, Takano EA, Bates GJ, Brown PJ, Banham AH, Fox SB.

J Clin Pathol. 2009 Oct;62(10):896-902. doi: 10.1136/jcp.2009.065169. Epub 2009 Jul 20.

PMID:
19622517
9.

Genomic profiling of breast tumours in relation to BRCA abnormalities and phenotypes.

Stefansson OA, Jonasson JG, Johannsson OT, Olafsdottir K, Steinarsdottir M, Valgeirsdottir S, Eyfjord JE.

Breast Cancer Res. 2009;11(4):R47. doi: 10.1186/bcr2334. Epub 2009 Jul 9. Erratum in: Breast Cancer Res. 2009;11(5):404.

10.

Basal-HER2 phenotype shows poorer survival than basal-like phenotype in hormone receptor-negative invasive breast cancers.

Liu H, Fan Q, Zhang Z, Li X, Yu H, Meng F.

Hum Pathol. 2008 Feb;39(2):167-74. Epub 2007 Nov 28.

PMID:
18045647
11.

Phenotypic characterization of BRCA1 and BRCA2 tumors based in a tissue microarray study with 37 immunohistochemical markers.

Palacios J, Honrado E, Osorio A, Cazorla A, Sarrió D, Barroso A, Rodríguez S, Cigudosa JC, Diez O, Alonso C, Lerma E, Dopazo J, Rivas C, Benítez J.

Breast Cancer Res Treat. 2005 Mar;90(1):5-14.

PMID:
15770521
12.

Sporadic invasive breast carcinomas with medullary features display a basal-like phenotype: an immunohistochemical and gene amplification study.

Rodríguez-Pinilla SM, Rodríguez-Gil Y, Moreno-Bueno G, Sarrió D, Martín-Guijarro Mdel C, Hernandez L, Palacios J.

Am J Surg Pathol. 2007 Apr;31(4):501-8.

PMID:
17414096
13.

Microcephalin is a new novel prognostic indicator in breast cancer associated with BRCA1 inactivation.

Richardson J, Shaaban AM, Kamal M, Alisary R, Walker C, Ellis IO, Speirs V, Green AR, Bell SM.

Breast Cancer Res Treat. 2011 Jun;127(3):639-48. doi: 10.1007/s10549-010-1019-4. Epub 2010 Jul 15.

PMID:
20632086
14.

Inference of the Basal epithelial phenotype in breast carcinoma from differential marker expression, using tissue microarrays in triple negative breast cancer and women younger than 35.

Nassar A, Sussman ZM, Lawson D, Cohen C.

Breast J. 2012 Sep;18(5):399-405. doi: 10.1111/j.1524-4741.2012.01279.x. Epub 2012 Aug 10.

PMID:
22882580
15.

Familial breast cancers without mutations in BRCA1 or BRCA2 have low cyclin E and high cyclin D1 in contrast to cancers in BRCA mutation carriers.

Aaltonen K, Blomqvist C, Amini RM, Eerola H, Aittomäki K, Heikkilä P, Nevanlinna H.

Clin Cancer Res. 2008 Apr 1;14(7):1976-83. doi: 10.1158/1078-0432.CCR-07-4100.

16.

Relationship of patients' age to histopathological features of breast tumours in BRCA1 and BRCA2 and mutation-negative breast cancer families.

Eerola H, Heikkilä P, Tamminen A, Aittomäki K, Blomqvist C, Nevanlinna H.

Breast Cancer Res. 2005;7(4):R465-9. Epub 2005 Apr 21.

17.

Triple negative breast cancer: a study from the point of view of basal CK5/6 and HER-1.

Pintens S, Neven P, Drijkoningen M, Van Belle V, Moerman P, Christiaens MR, Smeets A, Wildiers H, Vanden Bempt I.

J Clin Pathol. 2009 Jul;62(7):624-8. doi: 10.1136/jcp.2008.061358.

PMID:
19561231
18.

Does vimentin help to delineate the so-called 'basal type breast cancer'?

Kusinska RU, Kordek R, Pluciennik E, Bednarek AK, Piekarski JH, Potemski P.

J Exp Clin Cancer Res. 2009 Aug 20;28:118. doi: 10.1186/1756-9966-28-118.

19.

Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma.

Livasy CA, Karaca G, Nanda R, Tretiakova MS, Olopade OI, Moore DT, Perou CM.

Mod Pathol. 2006 Feb;19(2):264-71.

20.

Distinction between hereditary and sporadic breast cancer on the basis of clinicopathological data.

van der Groep P, Bouter A, van der Zanden R, Siccama I, Menko FH, Gille JJ, van Kalken C, van der Wall E, Verheijen RH, van Diest PJ.

J Clin Pathol. 2006 Jun;59(6):611-7. Epub 2006 Apr 7.

Supplemental Content

Support Center